Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (41-50 of 192) with videos related to

Pageof 20
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|June 23, 2026
Diagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral SpondyloarthritisWannes Van Hooste, Josephine Braekman, Thomas Renson, et al.
Arthritis and Rheumatism|June 30, 2005
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritisLeen De Rycke, Dominique Baeten, Elli Kruithof, et al.
Drugs|November 26, 2004
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitisFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Arthritis and Rheumatism|March 29, 2002
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathyFilip Van Den Bosch, Elli Kruithof, Dominique Baeten, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Current Rheumatology Reports|November 13, 2002
Gut inflammation and spondyloarthropathiesFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Clinical and Experimental Rheumatology|November 18, 2017
Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international studySílvia Fernandes, Adrien Etcheto, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|May 13, 2016
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)Vibeke Strand, Philip Mease, Laure Gossec, et al.
Annals of the Rheumatic Diseases|August 20, 2013
Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS studySofia Ramiro, Carmen Stolwijk, Astrid van Tubergen, et al.
Pageof 20

Showing results (41-50 of 192) with videos related to

Sort By:
Pageof 20
Arthritis & Rheumatology (Hoboken, N.J.)|June 23, 2026
Diagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral SpondyloarthritisWannes Van Hooste, Josephine Braekman, Thomas Renson, et al.
Arthritis and Rheumatism|June 30, 2005
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritisLeen De Rycke, Dominique Baeten, Elli Kruithof, et al.
Drugs|November 26, 2004
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitisFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Rheumatology and Therapy|May 6, 2017
Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Arthritis and Rheumatism|March 29, 2002
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathyFilip Van Den Bosch, Elli Kruithof, Dominique Baeten, et al.
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Current Rheumatology Reports|November 13, 2002
Gut inflammation and spondyloarthropathiesFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Clinical and Experimental Rheumatology|November 18, 2017
Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international studySílvia Fernandes, Adrien Etcheto, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|May 13, 2016
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)Vibeke Strand, Philip Mease, Laure Gossec, et al.
Annals of the Rheumatic Diseases|August 20, 2013
Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS studySofia Ramiro, Carmen Stolwijk, Astrid van Tubergen, et al.
Pageof 20